We have identi®ed two novel proteins that interact speci®cally with the C-terminal repression domain of Interferon Regulatory Factor-2 (IRF-2). These proteins, which we term IRF-2 binding proteins 1 and 2 (IRF-2BP1 and IRF-2BP2, the latter having two splicing isoforms, A and B), are nuclear proteins, and have the properties of IRF-2-dependent transcriptional co-repressors that can inhibit both enhancer-activated and basal transcription in a manner that is not dependent upon histone deacetylation. IRF-2BP1 and IRF-2BP2A/B contain an N-terminal zinc ®nger and a C-terminal RING ®nger domain of the C3HC4 subclass, but show no homology to other known transcriptional regulators; they therefore de®ne a new family of corepressor proteins. An alternatively spliced form of IRF-2 that lacks two amino acids (valines 177 and 178) in the central portion of the protein (IRF-2[S]) cannot bind to these co-repressors and cannot mediate repression despite having the same Cterminal repression domain as IRF-2, suggesting that the relative conformation of the DNA binding domain and the C-terminal region of IRF-2 is crucial for transcriptional repression.
INTRODUCTION
Interferon Regulatory Factor-2 (IRF-2) is a member of a family of proteins (the IRFs) that play a major role in the transcriptional regulation of type I interferon (IFN) genes in response to viral infection and genes that are regulated in response to type I and type II IFNs [reviewed in (1) ]. IRF-2 was originally described as a protein that bound to the IFN-b promoter and antagonised the effect of the transcriptional activator, IRF-1 (2) . Further studies have implicated IRF-2 as a negative regulator of many IFN-responsive genes that contain IRF binding sites in their promoters [for example, 2¢-5¢-oligoadenylate synthetase, iNOS, MHC class I; reviewed in (1) ]. Consistent with this, mice lacking IRF-2 demonstrate dramatic over-expression of genes induced by type I IFN, and develop an in¯ammatory skin disease in response to antigenic stimulation, indicating that IRF-2 plays an essential role in modulating the response to IFN (3) . As many of these genes play a role in the negative regulation of the cell cycle and/or apoptosis, IRF-2 is also a putative oncogene (4±6).
In addition to its ability to inhibit expression of some genes, IRF-2 has been shown to be a transcriptional activator of others. This was ®rst shown for the cell-cycle regulated transcriptional activation of the histone H4 gene (7, 8) and has since been demonstrated for the gp91 phox (9) , EBV EBNA-1 (10) , vascular cell adhesion molecule-1 (11) and MHC class II transactivator (CIITA) genes (12, 13) . A requirement for IRF-2 in CIITA transactivation is supported by the ®nding that mutations in the IRF-2 DNA binding domain (DBD) are found in a pancreatic tumour cell line and in fresh pancreatic tumour explants and are associated with loss of CIITA transcription (14) .
Analysis of the domain structure of IRF-2 shows that the N-terminal 113 amino acids encompass the highly conserved IRF DBD containing a characteristic motif consisting of ®ve tryptophan residues, which forms a`winged helix' structure (15, 16) . The transcriptional activation domain (AD) has been shown to reside between amino acids 160 and 220 (11, 17) . On promoters that are not activated by IRF-2 the transactivation domain is dominantly inhibited by the C-terminus (17) , and the C-terminus of IRF-2 can also repress transcription when fused to a heterologous DBD (17, 18) , indicating that this region of IRF-2 contains an autonomously acting repression domain.
The mechanisms of repression and transactivation by IRF-2 are poorly characterised, but it has been shown that IRF-2 can interact with the histone acetylase factors, GCN5, PCAF and p300/CBP (19) , and with TFIIB (20) , all of which are known to play important roles in transcriptional stimulation. Furthermore, a cDNA for the bromodomain-containing protein, Celtix-1, has been isolated from a yeast two-hybrid screen using IRF-2 as bait, and it has been suggested that Celtix-1 may play a role in transactivation by IRF-2 (21) . It is also possible that IRF-2 activates transcription by recruiting IRF-1 to some promoters (12) . To date, no factors capable of interacting with the C-terminal repression domain have been identi®ed. In this manuscript we describe the cloning and characterisation of two novel nuclear proteins (which we call IRF-2 binding proteins 1 and 2; IRF-2BP1 and IRF-2BP2) that bind to the C-terminal repression domain and have the properties of IRF-2-dependent transcriptional corepressors that can inhibit both enhancer-activated and basal transcription. 
MATERIALS AND METHODS

Plasmids
Schematics of the reporter gene and effector plasmids used in this report are shown in Figure 1 (22, 23) . The GAL4-responsive minimal promoter reporter construct, p(GALUAS) 5 tkD(±39)lucter, was constructed by inserting the ®lled-in HindIII±XbaI fragment containing the GALUAS pentamer from pG5E4CAT (24) into BamHI-linearised and ®lled-in ptkD(±39)lucter. pSV40-(GALUAS) 5 tkD(±39)lucter contains the SV40 enhancer fragment (SV40 co-ordinates 272 to 100 from pSVHNE) (25) inserted upstream of the GALUAS in p(GALUAS) 5 tkD-(±39)lucter. In pSV40(lacP/O)tkD(±39)lucter the GALUAS pentamer was replaced by the 70 bp BamHI±BglII polylinker fragment from pVX (26) to create a GAL4-unresponsive SV40 enhancer-driven luciferase reporter. All luciferase reporter plasmids were co-transfected with pJATlac, a plasmid in which the Escherichia coli b-galactosidase gene is under the control of the constitutively active rat b-actin promoter (27) . In p(GALUAS) 5 tkD(±39)b-globin, the luciferase gene of p(GALUAS) 5 tkD(±39)lucter is replaced by a genomic fragment of human b-globin (co-ordinates ±5 to +2160 relative to the b-globin cap site). The plasmid pSVHSa118 (28), which directs the constitutive expression of human a-globin, was used as a co-transfection control in b-globin experiments.
Expression in mammalian cells was achieved using pEF.plink2 (29) . pEF.IRF-1 and pEF.IRF-2 contain fulllength cDNAs for IRF-1 and IRF-2, respectively, cloned between the NcoI and XbaI sites of pEF.plink2. pEF.IRF-2BP1, pEF.IRF-2BP2A and pEF.IRF-2BP2B contain fulllength open reading frames from pGAD10 clones isolated from the yeast two-hybrid screen described below; each of these clones is N-terminally tagged with the SV5 epitope tag. pEF.GAL147 contains the DBD (amino acids 1±147) of the yeast GAL4 transcription factor cloned between the NcoI and EcoRI sites of pEF.plink2. To construct pEF.GALIRF-
pEF.GALIRF-2(292±349), pEF.GALIRF-2(332±349), pEF.GALIRF-2(292±340) and pEF.GALIRF-2(292±330), the indicated fragments of IRF-1 or IRF-2 were generated from precursor plasmids and fused in-frame to the GAL4 DBD of pEF.GAL147 using standard procedures; all end-points and fusion junctions were veri®ed by dideoxy sequencing. A plasmid related to pEF.GALIRF-2(88±349) but expressing the equivalent IRF-2 fragment from the IRF-2[S] isoform [pEF.GALIRF-2[S](88±347)] was constructed from a full-length IRF-2[S] cDNA isolated from Jurkat cells by RT±PCR.
pEF.GALIRF-2BP1, pEF.GALIRF-2BP2A, pEF.GALIRF-2BP2B and pEF.GALIRF-2BP2(456±587) were constructed by inserting cDNA fragments from pGAD10 clones in-frame with and downstream of amino acid 147 of the GAL4 DBD of pEF.GAL147. pHON1 and pHON3 allow the expression of GAL4 DBD and AD fusions, respectively, in yeast, and are derived from pGBT9 and pGAD424 (30) by replacing the part-length ADH promoter with the full-length ADH promoter from pAS2-1 (31); these vectors also contain additional cloning sites in their polylinkers. To construct pHON1.IRF-2(1±349), pHON1.IRF-2(1±224), pHON1.IRF-2(1±163), pHON1.IRF-2(172±349), pHON1.IRF-2(224±349), pHON1.IRF-2(269±349), pHON1. IRF-2(292±349) and pHON1.IRF-2(332±349), and pHON1. IRF-2[S](1±347), IRF-2 or IRF-2[S] fragments were, respectively, generated from precursor plasmids and fused in-frame to the GAL4 DBD of pHON1. pHON1.IRF-2BP1, pHON1.IRF-2BP2A, pHON1.IRF-2BP2B and pHON1.IRF-2BP2(456±587) were constructed by transferring the EcoRI cDNA fragments from the pGAD10 clones into the EcoRI site of pHON1. To construct pHON3.IRF-1(1±325), pHON3.IRF-2(292±349), pHON3.IRF-9, fragments of IRF-1, IRF-2 or IRF-9 were generated from precursor plasmids and fused inframe to the GAL4 AD of pHON3. Plasmids for the expression of fusions with either DBD (pHON1) or AD (pHON3 or pGAD424) and p65, Jak1, STAT1a and PKR (Table 1) were constructed in this laboratory using standard procedures (details available on request).
Yeast two-hybrid library screen
Saccharomyces cerevisiae PJ69-4a (MATa, ura3-52, his3-200, ade2-101, trp 1-901, leu2-3, 112, gal4D, gal80D, GAL2-ADE2, LYS2::Gal1-HIS3 met2::GAL7-lacZ) (32) was transformed (33) with the IRF-2 bait plasmid pHON1.IRF-2[292±349]. This strain was transformed with a human placental cDNA library in the GAL4 AD vector pGAD10 (Clontech catalogue number HL4003AB) and selected on SD medium plus 2 mM 3-aminotriazole but lacking tryptophan, leucine and histidine. From a total of 10 7 yeast colonies screened (equivalent to a 3±4-fold representation of the library), 209 colonies were selected, and of these, 43 also grew on SD medium lacking adenine. Plasmid DNA was recovered from each of these colonies by marker rescue in E.coli KC8 (hsdR, leuB600, trpC9830, pyrF::Tn5, hisB463, lacDX74, strA, galU, K), transformed into PJ69-4a (32) and the individual transformants were mated with PJ69-4a carrying either pHON1 or pHON1.IRF-2[292±349] and the diploids tested for the ability to rescue growth on SD lacking adenine. DNA from 36 primary yeast colonies rescued adenine auxotrophy in a bait-dependent manner. The cDNA inserts were found to fall into four classes (see Fig. 3A ). To con®rm the interactions, the cDNA insert from a representative of each class was fused in-frame to the DBD of GAL4 (in pHON1) and tested for the ability to rescue adenine auxotrophy in combination with the C-terminal repression domain of IRF-2 fused in-frame to the AD of the yeast GAL4 protein (pHON3.IRF-2[292±349]). The cDNA inserts from the pGAD10 clones were sequenced using a combination of manual and automated (Oswel and Lark Technologies) dideoxy sequencing.
Immunoprecipitation and western blotting
Cell lysates were prepared in RIPA buffer (~5 Q 10 6 cells in 500 ml), and 100 ml aliquots were pre-cleared using preimmune serum and protein A±Sepharose (Pharmacia) using standard procedures. One microlitre of anti-IRF-2 (34) was added to the supernatant and incubated at 4°C for 1 h, and then speci®c complexes were collected on protein A±Sepharose beads by centrifugation. The beads were washed four times in 1 ml RIPA buffer, then resuspended in 20 ml 2Q Laemmli's buffer. Samples were heated to 95°C for 5 min, fractionated by SDS±PAGE, blotted onto 0.45 m PVDF, probed with a monoclonal antibody raised against the SV5 PK epitope tag and visualised using enhanced chemiluminescence according to the manufacturers' recommendations (Amersham). GAL4 DBD fusions were detected in extracts from yeast or transiently transfected 293 cells using a monoclonal antibody purchased from Clontech (catalogue number 5399-1) under the manufacturer's recommended conditions.
Transfection and analysis of gene expression
HeLaE cells (E.Laufer, ICRF) were cultured and transfected as described previously (35) . For all transfections except that shown in Figure 5C (see ®gure legend), plasmids were mixed in a relative mass ratio of three parts reporter construct:three parts transfection control construct:four parts effector. Luciferase and b-galactosidase levels were determined as described previously (22) . Cellular RNA was prepared from transiently transfected cells and analysed by RNase protection Table 1 . Interactions between IRF-2BPs and cellular proteins
PJ69-4a-derivative yeast strains transformed with the indicated`bait' proteins as GAL4 DBD fusions were mated with PJ69-4a-derivatives transformed with the indicated`prey' proteins as GAL4 AD fusions (see Materials and Methods). Successful matings were selected on SD-Leu-Trp and diploid colonies were streaked in triplicate onto SD-Leu-Trp, SD-Leu-Trp-His and SD-Leu-Trp-Ade and their growth was monitored. Absence of interaction resulted in no growth after 6 days on SD-Leu-Trp-His and SD-Leu-Trp-Ade (indicated by`±'); positive interactions were graded according to the following scale: + = growth on SD-leu-trp-his, but no growth on SD-leu-trp-ade after 6 days; ++ = abundant growth on SD-leu-trp-his and limited growth on SD-leu-trp-ade after 4 days; +++ = abundant growth on SD-leu-trp-his and on SD-leu-trp-ade after 4 days; ++++ = abundant growth on SD-leu-trp-his and on SD-leu-trp-ade after 2 days; ND = interaction not determined. All diploids showed equivalent growth on SD-Leu-Trp indicating that growth rates are unaffected by competition for yeast transcription factors (`squelching'). The relative expression levels of the GAL4-IRF-2 fusions were determined by western blotting and found to be comparable (data not shown). Attempts to quantitate the strengths of interaction using the GAL7-lacZ reporter gene in the PJ69 yeast strains (32) were unsuccessful due to high background b-galactosidase activity.
using human a-globin-and b-globin-speci®c probes (28) .
Where indicated, cells were treated with 200 nM trichostatin A (Sigma) in DMSO or 0.01% v/v DMSO as a control for 26 h prior to harvesting.
RESULTS
The IRF-2 C-terminal domain can repress both activated and basal transcription
Although it has been shown previously that C-terminal fragments of IRF-2 can inhibit adjacent activators when fused to a heterologous DBD, the precise requirements for repression appear to vary depending upon the transcriptional activator used (17, 18) . To clarify this situation we initially examined the ability of GAL4-IRF-2 fusions to repress transcription from a promoter containing a synthetic multimer of the DNA binding site for GAL4 inserted between the TATA box of HSV-1 and the SV40 enhancer [pSV40(GALUAS) 5 tkD(±39)lucter]. Figure 2A shows that a fusion with IRF-2 amino acids 88±349 [GAL.IRF-2(88±349)] represses SV40-driven transcription in contrast to the properties of the GAL4 DBD alone (compare lanes 1 and 3); as expected, a fusion between GAL4 and IRF-1 [GAL.IRF-1(105±325)] strongly activated transcription (lane 2). These effects were dependent upon GAL.IRF-2(88±349) recruitment to the promoter since repression was not seen when the multimeric GAL UAS was replaced with a random sequence of DNA of similar length [pSV40(lacP/ O)tkD(±39)lucter; data not shown].
Removal of the C-terminal 69 amino acids [GAL.IRF-2(88±280)] led to a complete loss of repression ( Fig. 2A, lane  4) , indicating, as expected, that residues in this region contribute to negative regulation. Constructs containing as few as 58 amino acids from the extreme C-terminus [GAL.IRF-2(292±349)] are capable of repressing transcription to the same extent as the full-length protein, whilst a fusion containing the C-terminal 18 amino acids [GAL.IRF-2(332±349)] only showed~30% of this repression ( Fig. 2A,  lanes 5±8 ). Removal of the nine C-terminal-most amino acids from the GAL.IRF-2(292±349) construct [GAL.IRF-2(292±340)] had no effect, whilst removal of the 19 Cterminal-most amino acids [GAL.IRF-2(292±330)] completely eliminates repression ( Fig. 2A, lanes 9 and 10) . Thus, amino acids 292±340 of IRF-2 contain an independently acting repression domain, which is strongly conserved between species (see Fig. 1C ).
We also investigated whether GAL4-IRF-2 fusions could repress transcription from a minimal promoter (i.e. a promoter The yeast two-hybrid cDNA library screen generated ®ve independent isolates of a 2579 bp insert that encodes IRF-2BP1. This sequence derives from an uncharacterised gene on chromosome 19 (GenBank accession number AC008623, nucleotides 134839±137352). The ®rst in-frame ATG is located 348 bp from the 5¢ end of the insert; this was determined to be the initiating methionine, as an in-frame stop codon is present 600 bp upstream from this in the genomic sequence, and no EST clones have been identi®ed containing upstream sequences. The ATG is followed by an uninterrupted open reading frame of 584 amino acids followed by a 3¢UTR, polyadenylation signal (AATAAA) and a poly(A) tail. A single isolate of the insert shown for IRF-2BP2A was obtained. The insert comprises~2500 bp derived from an uncharacterised gene on chromosome 1 (GenBank accession numbers AL161640, nucleotides 28362±30847, and AL160408 nucleotides 4723±2239). Due to the high G-C content of the 5¢ end of this insert (and that for IRF-2BP2B; see below) we were unable to obtain accurate sequence data at the 5¢ end and we note that the available sequences of both genomic clones and the ESTs stop in the same place. We have tentatively assigned the initiator ATG for IRF-2BP2A on the basis that: (i) the sequence is identical to IRF-2BP2B and very similar to IRF-2BP1 in this region; (ii) the encoded protein initiating from this ATG is highly homologous to proteins found in Drosophila and C.elegans proteins (see text and B); (iii) the assigned initiator ATG conforms to the consensus Kozak sequence; (iv) such G-C-rich sequences are frequently found in 5¢UTRs. The ATG is followed by an open reading frame of 587 amino acids, which is terminated by a 3¢ TAG stop codon; this cDNA clone does not have a poly(A) tail. Two independent isolates of the 2600 bp insert encoding IRF-2BP2B were obtained. IRF-2BP2A and IRF-2BP2B differ in the size of the single intron, and thus represent alternative splice forms of a single gene. IRF-2BP2B lacks 48bp, representing 16 amino acids, that are present in IRF-2BP2A. The presumptive splice acceptor site is the same in both inserts (AL161640 nucleotide 30026) and conforms to the consensus of 10 pyrimidines followed by NCAG. The presumptive donor sites are AGGT at nucleotide 29433 for IRF-2BP2A and AGGC at nucleotide 29385 for IRF-2BP2B. We also recovered 28 independent isolates of the indicated insert of 775 bp that encodes a 3¢ region common to both IRF-2BP2A and IRF-2BP2B. (B) The primary amino acid sequences of IRF-2BP1 and IRF-2BP2 are aligned with each other using the BLAST pairwise programme and common residues are highlighted in black (functionally conserved residues are highlighted in grey). The asterisk-underlined sequence shown in IRF-2BP2A is not present in IRF-2BP2B. The conserved zinc ®nger and C3HC4 RING domains at the N-and C-terminus, respectively, are boxed and the cysteines and histidines are indicated. Homologies with the hypothetical human C14orf4 (polyQ) protein, and the C.elegans MO4G12 and the D.melanogaster CG11138 and CG1855 gene products in these regions are indicated. that lacks identi®able upstream activator sequences). Figure 2B shows that GAL.IRF-2(88±349) is capable of repressing transcription from a promoter containing a synthetic multimer of the DNA binding site for GAL4 placed upstream of the TATA box of HSV-1 [p(GALUAS) 5 tkD (±39)lucter]; the repressive effects of other GAL4.IRF-2 fusions on this promoter were very similar to those seen on SV40-driven transcription, although repression by GAL.IRF-2(332±349) was slightly more ef®cient on the minimal promoter. The ability of IRF-2 to mediate repression of a minimal promoter has not been reported previously.
To con®rm that the effects of GAL-IRF fusions are operating at the level of transcription, we analysed RNA from transient transfections of the fusions and a reporter gene consisting of a human b-globin gene under the control of a minimal promoter [p(GALUAS) 5 tkD(±39)b-globin]. Figure 2D shows that transcription from this promoter is markedly repressed by GAL.IRF-2(88±349); as expected, transcription is strongly stimulated by expression of GAL.IRF-1(105±325).
Isolation of cDNA clones encoding proteins that interact with the C-terminal repression domain of IRF-2
We next sought to identify interacting partners for the Cterminus of IRF-2 using the yeast two-hybrid system. Thirtysix colonies containing veri®able bait-dependent partners were isolated from a total of 10 7 yeast colonies of a human placental cDNA library screened with a fusion containing IRF-2 amino acids 292±349 (see Materials and Methods). The cDNA inserts in these colonies were mapped and sequenced and shown to encode two novel related products [referred to hereafter as IRF-2-binding proteins 1 and 2; IRF-2BP1 (GenBank accession number AY278022) and IRF-2BP2], with two distinct splicing isoforms of IRF-2BP2 being isolated [IRF-2BP2A (GenBank accession number AY278023) and IRF-2BP2B (GenBank accession umber AY278024) that lacks 16 amino acids present in IRF-2BP2A; see Fig. 3A] .
The translated ORFs of IRF-2BP1 and IRF-2BP2A encode proteins of 584 and 587 amino acids, respectively, with IRF-2BP2B encoding 571 amino acids. IRF-2BP1 and IRF-2BP2A/B are related proteins with two highly conserved regions (Fig. 3B) ; at the N-terminus there is a 64 amino acid domain which contains a single C4 zinc ®nger motif, and at the C-terminus the ®nal 82 amino acids encompass a C3HC4 or RING ®nger. The IRF-2BPs are also related to a third human cDNA that encodes a hypothetical protein of unknown function called C14orf4 (36) , and to the Caenorhabditis elegans MO4G12 and the Drosophila melanogaster CG11138 and CG1855 gene products, also of unknown function. The Cterminal RING ®nger of IRF-2BP2 is suf®cient for the interaction with IRF-2 since we had isolated an insert encoding amino acids 456±587 of IRF-2BP2A/B as a primary interacting clone in our library screen.
The speci®city of interaction of IRF-2BP1, IRF-2BP2A and IRF-2BP2B with other members of the IRF family was investigated using the yeast two-hybrid assay. Whilst all three proteins could interact with GAL.IRF-2 fusions containing a variety of C-terminal IRF-2 fragments (see below), they were not capable of interacting with fusions with the C-terminal effector domains of IRF-1 or IRF-9 (Table 1) . Furthermore, interactions could not be observed with non-IRF preys (Jak-1, STAT1, PKR or the p65 subunit of NF-kB; Table 1 ). IRF-2BP1, IRF-2BP2A and IRF-2BP2B failed to interact with themselves or each other indicating that they may not be able to form dimers.
The IRF-2 domain dependence for IRF-2BP binding was investigated in more detail. None of IRF-2BP1, IRF-2BP2A and IRF-2BP2B interacted with IRF-2 fragments lacking the C-terminal region (Table 1 ). These data show that the Cterminal 58 amino acids of IRF-2 are necessary and suf®cient for interaction with the IRF-2BPs. Although all of the IRF-2BP fusions interacted with the IRF-2 repression domain encoding amino acids 292±349, IRF-2BP1 was capable of interacting with fusions containing just the C-terminal 18 amino acids of IRF-2 (amino acids 332±349), albeit weakly ( Table 1) .
The fact that multiple copies of cDNAs encoding two highly related IRF-2-interacting partners were the only factors isolated from a library screen of~4-fold transcriptome equivalents strongly suggests that the IRF-2BPs are physiologically important partners for IRF-2. To verify interaction with IRF-2 in vivo we constructed vectors that permitted mammalian expression of epitope-tagged forms of IRF-2BP1, IRF-2BP2A or IRF-2BP2B, and transiently transfected them into HeLa cells. Whole cell extracts were prepared from these cells and immunoprecipitated with a rabbit polyclonal antibody raised against IRF-2 (34) and the immunoprecipitates were fractionated on an SDS±polyacrylamide gel and analysed by western blotting using a monoclonal antibody that recognised the epitope tag. Figure 4A shows that each of the IRF-2BPs is co-immunoprecipitated, indicating a strong interaction with IRF-2. To determine the sub-cellular localisation of the IRF-2BPs, transiently transfected cells were harvested and both cytoplasmic and nuclear extracts prepared and analysed by western blotting. Figure 4B shows that, as expected for factors that interact with IRF-2 and potentially regulate transcription, each of IRF-2BP1, IRF-2BP2A and IRF-2BP2B is localised to the nucleus.
IRF-2BP1 and IRF-2BP2 are novel co-repressor proteins
To investigate the function of IRF-2BP1, IRF-2BP2A and IRF-2BP2B we initially examined their effect on transcription when tethered to promoters through the DBD of GAL4. IRF-2BP1, IRF-2BP2A and IRF-2BP2B are all capable of specifically repressing transcription on both SV40-driven (Fig. 5A) and minimal (Fig. 5B) promoters. The magnitude of repression is similar to that seen with a GAL4 fusion to a fragment of IRF-2 spanning amino acids 88±349. Interestingly, although a fusion with just the RING domain of IRF-2BP2 (amino acids 456±587) is unable to repress transcription from the SV40-driven promoter (Fig. 5A) , it retains the ability to repress transcription from a minimal promoter (Fig. 5B) . The repression effects were dependent upon recruitment of GAL4 fusion proteins to the promoter since repression was not seen when the multimeric GAL UAS was replaced with a random sequence of DNA [pSV40(lacP/O)tkD(±39)lucter], nor with reporters under the control of other promoters lacking a GAL UAS [ptkD(±39)lucter; ptkD(±105)lucter; data not shown].
To test whether IRF-2BP1/2 retain the ability to repress transcription when recruited to DNA indirectly through association with IRF-2, we examined whether they could enhance the degree of repression exerted by GAL.IRF-2 fusions. Figure 5C shows that repression by GAL.IRF-2 could be signi®cantly enhanced by co-expression of IRF-2BP1 or IRF-2BP2A (IRF-2BP2B was not tested in this experiment). We conclude from this that IRF-2BP1 and IRF-2BP2A can repress transcription by their recruitment to promoters by IRF-2.
In order to test whether the IRF-2BPs affect transcriptional regulation through IRFs bound to their cognate DNA binding sites we investigated the behaviour of the IRF-dependent promoter, [p[(AAGTGA)4] 5 tkD(±39)lucter], in transient transfection experiments. We have shown previously that the activity of this reporter in HeLa cells represents a balance of the opposing activities of IRF-1 and IRF-2 (23) . Figure 5D (lane 1) shows that in the absence of co-transfected IRF expression plasmids this reporter is only weakly active; this observation was expected since HeLa cells contain abundant IRF-2 but no detectable IRF-1 (34) . The activity is strongly stimulated by IRF-1 expression (Fig. 5D, lane 2) , and this stimulation is antagonised by co-expressing IRF-2 (Fig. 5D,  lane 3) . Co-transfection of expressing plasmids for IRF-2BP1 (Fig. 5D, lane 4) , and IRF-2BP2A (Fig. 5D, lane 5) , reduced IRF-1-dependent activation to 20±30%, whilst IRF-2BP2B (Fig. 5D, lane 6) , reduced activation to~60%. Since the IRF-2BPs were unable to in¯uence the transcriptional activity of IRF-1 when examined as a GAL4 fusion (the function of which is independent of IRF-2; data not shown), and were unable to interact with IRF-1 in the yeast two-hybrid assay (Table 1) , the effects of IRF-2BP1, IRF-2BP2A and IRF-2BP2B are likely acting through endogenous IRF-2, and thus they repress transcription in an IRF-2-dependent manner.
Repression by IRF-2 and the IRF-2BP co-repressors is still seen in the presence of a histone deacetylase inhibitor
Many transcriptional repressors exert their effect either directly or indirectly through the deacetylation of histones in the vicinity of their binding site [reviewed in (37) ]. To test whether IRF-2 and its associated co-repressors work in this manner we treated cells with the histone deacetylase (HDAC) inhibitor trichostatin A. Figure 6 shows that repression of SV40-driven transcription by the GAL.IRF-2(88±349) fusion is unaffected by trichostatin A suggesting that it is HDACindependent. Although transcriptional repression by GAL4 fusions with IRF-2BP1, IRF-2BP2A or IRF-2BP2B was seen in the presence and absence of trichostatin A, repression by IRF-2BP1 and IRF-2BP2A is partially relieved by the addition of trichostatin A. This effect was not seen with IRF-2BP2B, which retained full repression in the presence of trichostatin A. These results suggest that the IRF-2BPs must exert a signi®cant part of their repressive activity through a mechanism(s) that is independent of histone deacetylation.
An isoform of IRF-2, IRF-2[S], which lacks two amino acids, cannot interact with the IRF-2BPs nor repress transcription
During the course of our investigations we identi®ed a form of IRF-2 that lacks valine 177 and valine 178; this alternative form of IRF-2 lacks 6 bp that derive from the exon 5/exon 6 junction and has recently been described by others (38) , and according to their convention we refer to this alternative form as IRF-2[S]. It was reported that IRF-2[S] is a less ef®cient transcriptional activator of the CIITA promoter than IRF-2 (38) . In order to test whether the repressive activities of IRF-2[S] and IRF-2 are also different we constructed a GAL.IRF-2[S] fusion containing the equivalent of amino acids 88±349 [GAL.IRF-2[S](88±347)] and compared its ability to repress transcription with that seen with GAL.IRF-2(88±349). Figure 7A and B show that the IRF-2[S] fusion is unable to repress transcription from either the enhancer-activated or basal reporter genes. This result is surprising since both forms of IRF-2 contain an identical C-terminal repression domain (292±349) that is suf®cient for repression when fused to GAL4 and suf®cient for strong interaction with the IRF-2BPs.
To con®rm that the effects of GAL.IRF fusions are operating at the level of transcription, we analysed RNA from transient transfections of the fusions and a reporter gene consisting of a human b-globin gene under the control of a minimal promoter. Figure 7C shows that transcription from this promoter is markedly repressed by GAL.IRF-2(88±349), whereas the IRF-2[S] counterpart, GAL.IRF-2[S](88±347)], is without effect.
One explanation for the difference in the negative regulatory properties of IRF-2 and IRF-2[S] may be that the Cterminal repression domains are in different conformations. Structural predictions for IRF-2 suggest that the loss of V177 and V178 disrupts the secondary structure in this region of IRF-2[S], and generates a protein which has an alternative b-sheet structure (38) . Whilst this putative structural change does not affect the ability of IRF-2[S] to bind to DNA, it may in¯uence the conformation of other domains and this has been suggested to account for the difference in transactivation IRF-2-BP1 and IRF-2BP2A/B have an N-terminal C4 zinc ®nger and a C-terminal C3HC4 RING ®nger, and these features are conserved between the IRF-2BPs and the uncharacterised human C14orf4 gene product (36) . This sequence is suf®ciently related to the IRF-2BPs that it is possible that the C14orf4 gene product also interacts with IRF-2, but we have not tested this. The IRF-2BPs are also related to the C.elegans MO4G12 and the D.melanogaster CG11138 and CG1855 gene products. In none of these cases has the function been ascertained; since IRF homologues do not occur in C.elegans or D.melanogaster the IRF-2BPs may be members of a wider group of proteins that interact with a range of transcription factors.
The C3HC4 RING is a feature found in diverse families of proteins (including some co-repressors) (39±41) and serves as a domain for protein±protein interaction [reviewed in (42) ]. A major function of the RING ®nger in some of these proteins is to serve as a bridge between E2 and E3 ubiquitin ligases [reviewed in (43) ], and in the case of NOT4 this activity is essential for repression by the CCR4±NOT complex (44) . Furthermore, members of the protein inhibitor of activated STATs (PIAS) family have recently been shown to act as SUMO E3 ligases; the transfer of SUMO to a number of transcriptional activators has been shown to alter their nuclear distribution and correlates with a down-regulation in their activity (45±51). Although we have yet to determine whether IRF-2BP1, IRF-2BP2A and IRF-2BP2B have ubiquitin or SUMO ligase activity it should be stressed that they have no homology with known ligases.
The RING ®nger motif of IRF-2BP2A/B (amino acids 456±587) is suf®cient to interact with the C-terminus of IRF-2, but is not suf®cient to repress enhancer-driven transcription, implying that some other region of IRF-2BP2A/B (and presumably IRF-2BP1) is responsible for repression. Additional regions of IRF-2BP1 and IRF-2BP2 have features in common with other repressors or co-repressors. Immediately after the N-terminal conserved C4 zinc ®nger is a segment rich in alanine, glutamine and proline residues (also present in the C14orf4 gene product where the extended alanine and glutamine stretch is inserted). There are also several clusters of prolines, another feature that is commonly found in or near to repression domains, as evidenced in p53 (52), Groucho (53) and HNF4 (54) .
Since C4 type zinc ®ngers are typically found in DBDs of proteins, it is possible that the N-terminal zinc ®nger of IRF-2BP1/2 can bind to DNA. If this is the case, then its role may be to stabilise the interaction of the IRF-2±IRF-2BP1/2 complex with the target promoter. It is also possible that this domain could mediate an interaction with another protein, either a transcription factor bound to the promoter adjacent to IRF-2 or a component of the basal transcriptional machinery.
Studies on co-repressors indicate that they often either possess or recruit HDAC activities to the target promoter and thereby modify local nucleosome structure to make the promoter less accessible to the transcriptional machinery [reviewed in (37) ]. Our experiments indicate that repression by GAL.IRF-2 fusions containing amino acids 88±349 of IRF-2 and by GAL.IRF-2BP2B is unaffected by an inhibitor of HDAC activity, and that repression by GAL.IRF-2BP1 and GAL.IRF-2BP2A is only partially sensitive to this inhibitor. These experiments suggest that repression by IRF-2 and its associated co-repressors does not depend upon histone deacetylation. This is consistent with observations on several other repressors (55±57). It is possible that the low level of HDAC-dependency seen with IRF-2BP1 and IRF-2BP2A re¯ects an activity that is required for repression when recruited to DNA through some transcription factor other than IRF-2.
Since the activity of the IRF-2BPs is largely independent of HDAC activity, repression must be achieved by other means. Several examples have been described in which repressors or co-repressors act by preventing the formation of a stable initiation complex. For example, the N-terminal repression domain of N-CoR has been shown to prevent the interaction between TFIIB and TAFII32 that is required for transcriptional activation (58) . We note that IRF-2BP1 can bind (albeit weakly) to a sub-region of the C-terminal repression domain of IRF-2 (amino acids 332±349), and that this IRF-2 subdomain is suf®cient to mediate repression of a minimal promoter, consistent with a repressor that is functioning by interference with the basal transcriptional machinery. We also note that at very high levels of expression, IRF-2BP1 exerts a limited degree of interference with promoters to which it should not bind (data not shown); this behaviour might be explained by sequestering some essential component of the basal transcriptional apparatus (commonly referred to as squelching). It is interesting to note that IRF-2 has been reported to interact with TFIIB (20) ; perhaps the IRF-2BPs prevent an interaction between IRF-2-bound TFIIB and another transcriptional co-factor. The IRF-2BPs might also act by preventing the recruitment or activity of the histone acetylases GCN5, PCAF and p300 to promoters by IRF-2 (19, 59) .
In a previous analysis of the repressor functions of IRF-2, Senger et al. were unable to identify a single domain that was capable of repressing a range of different GAL4-transactivator fusion proteins tethered to the DNA through a common site (18) . Instead, the magnitude of repression gradually diminished as more of IRF-2 was removed, with some activators requiring larger fragments of IRF-2 than others. The authors proposed that basic amino acids in the IRF-2 repression domain build a positively charged microenvironment that repels activator-recruited incoming CBP, or destabilises the CBP-activator interactions (18) . Such a model is intrinsically devoid of requirement for co-repressors. These results might also be explained if IRF-2 makes speci®c direct or indirect contacts with several individual components of the transcription machinery (and with chromatin and chromatin-modifying components) as seen for conventional transcriptional repressors. The identi®cation of the IRF-2BPs as IRF-2-dependent co-repressors is consistent with this hypothesis.
